SAR 428926
Alternative Names: SAR428926Latest Information Update: 15 Feb 2024
At a glance
- Originator ImmunoGen
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Taxanes
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 28 Nov 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Denmark (IV, Infusion)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in France (IV, Infusion)